Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Yentreve duloxetine: Phase III data

A post-hoc analysis of a double-blind, North American Phase III

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE